Viz

Planview Accelerates Transformation Impact with Next Generation Connectivity, Visibility, and AI-Driven Insights

Retrieved on: 
Wednesday, May 1, 2024
Software, Technology, Artificial Intelligence, Data Management, Organization, EAP, VSM, Commercial software, Data, Synthetic media, Universal, Work, Access, Electron capture, Generative, Amber, Viz, DPD

Planview® Copilot is now available across Strategic Portfolio Management, Enterprise Agile Planning (EAP), Value Stream Management (VSM), and Digital Product Development solutions, including the Planview® Portfolios, Planview® Viz, Planview® AdaptiveWork, and Planview® AgilePlace products.

Key Points: 
  • Planview® Copilot is now available across Strategic Portfolio Management, Enterprise Agile Planning (EAP), Value Stream Management (VSM), and Digital Product Development solutions, including the Planview® Portfolios, Planview® Viz, Planview® AdaptiveWork, and Planview® AgilePlace products.
  • Further boosting Planview’s AI-enabled platform capabilities, Planview is strengthening its early-warning systems with additional sentiment analysis and aggregation across key products, including Planview Portfolios, Planview® AgilePlace, and Planview® ProjectPlace.
  • Finally, Planview introduces the Planview® Universal Connector, a strong addition to the 60+ software tool connectors it already has available.
  • The Universal Connector enables organizations to automate and seamlessly integrate their third-party or homegrown software development tools directly into the Planview® Platform.

Viz.ai Wins 2024 Edison Award™ for Innovation for Second Year in a Row

Retrieved on: 
Friday, April 19, 2024
Cardiology, Biotechnology, Technology, Other Health, Health, General Health, Optical, Health Technology, Infectious Diseases, Software, Artificial Intelligence, Education, Mortality, FDA, AI, AVF, Triage, American Lung Association, Partnership, Artificial intelligence, Pulmonary embolism, Assessment, Engineering, Science, PERT, Edison Award, Edison Awards, Circulatory system, Thomas Edison, Multimedia, Marketing, Diagnosis, Viz

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced that it has been named an Edison Award Winner in the 2024 Edison Awards, for the second year in a row.

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced that it has been named an Edison Award Winner in the 2024 Edison Awards, for the second year in a row.
  • The prestigious Edison Awards, named after the American inventor Thomas Alva Edison, honor excellence in new product and service development, marketing, design and innovation.
  • View the full release here: https://www.businesswire.com/news/home/20240419954371/en/
    “We are honored to win our second Edison Award for innovation,” said Dr. Chris Mansi, CEO and co-founder of Viz.ai.
  • Winners were announced at the Edison Awards Gala on April 18, 2024 in Fort Myers, FL.

Viz.ai® Announces Three New Studies Supporting Viz HCM™ Module for the Detection and Management of Suspected Hypertrophic Cardiomyopathy

Retrieved on: 
Wednesday, April 3, 2024
Health, Technology, Hospitals, Health Technology, Software, Artificial Intelligence, Cardiology, Deep learning, FACC, Harvard Medical School, Machine learning, Cone Health Women's Hospital, PPV, Innovation, Algorithm, Artificiality, Assistant, Disease, Associate, Patient, Atlantic Health System, Triage, Salem Hospital, AI, Viz, American College, Massachusetts General Hospital, HCM, Hospital, Hypertrophic cardiomyopathy, Senior counsel, Sports cardiology, Hypertrophy, Medical director, Probability, FDA, ACC, ECG, Mass, Medical imaging

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in cardiology care.

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in cardiology care.
  • The Viz HCM module is the first and only AI algorithm cleared by the FDA for HCM.
  • The study found that Viz HCM performance in suspected HCM detection was consistent across various racial backgrounds with a sensitivity of 68.4% and specificity of 99.1%.
  • This validates the effectiveness of relevance score sorting for prioritizing higher probability HCM-positive patients identified by deep-learning algorithms analyzing ECG data.

Viz.ai and Medtronic Collaborate to Improve Post-Acute Stroke Patient Care in the United States

Retrieved on: 
Tuesday, March 26, 2024
Neurology, Cardiology, Software, Health, Artificial Intelligence, Hospitals, Health Technology, Technology, Stroke, Conductance quantum, Communication, Atrial fibrillation, Risk, Patient, AI, Arrhythmia, Medtronic, MD, Trial of the century, Viz, Service

Viz.ai, Inc., the leader in AI-powered disease detection and intelligent care coordination, today announced a strategic collaboration with Medtronic to improve the coordination of cryptogenic stroke patient care between the neurology and cardiology teams.

Key Points: 
  • Viz.ai, Inc., the leader in AI-powered disease detection and intelligent care coordination, today announced a strategic collaboration with Medtronic to improve the coordination of cryptogenic stroke patient care between the neurology and cardiology teams.
  • For stroke patients who are at risk of atrial fibrillation (“AF”) post-stroke and may need additional cardiac monitoring, stroke care teams in the U.S. will have the opportunity to use the Viz Connect™ solution, a software tool that automates the communication across disciplines, including neurology and cardiology.
  • Recent clinical study results indicate that both community hospitals and academic centers are in need of stronger, standardized care pathways between neurology and cardiology to ensure that stroke patients receive guideline-directed therapy.
  • According to the DiVERT Stroke clinical study, only 16% of stroke patients from community hospitals and 34% of patients at academic centers received a cardiology consult.1
    “Through our collaboration with Medtronic, we have the opportunity to bring cardiology and neurology closer together by using software tools that help facilitate stroke patient care,” said Chris Mansi, MD, CEO and co-founder at Viz.ai.

Viz.ai Broadens Healthcare System Integrations to Inform Critical Decisions at the Point of Care

Retrieved on: 
Tuesday, March 12, 2024
Data Management, Biotechnology, Technology, Health, General Health, Health Technology, Software, Artificial Intelligence, Networks, Internet, Mobile, Wireless, Pulmonary embolism, Algorithm, Good Samaritan Hospital, Disease, Patient, Intensive care unit, AI, MD, Viz, Workflow, FCCP, EHR, PACS, Multimedia, Physician, Medical imaging

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced expanded interoperability capabilities of Viz.ai One.

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced expanded interoperability capabilities of Viz.ai One.
  • Viz.ai algorithms and electronic health record (EHR) data work together on one platform to detect suspected disease and communicate results to care teams immediately.
  • These collaborative integrations streamline clinical workflows and help physicians diagnose and treat patients faster to improve patient outcomes.
  • “Viz.ai’s direct integrations provide more context and relevant patient information to clinicians wherever they are, helping to save more time at the point-of-care and increase efficiency.”

New Viz.ai Study Demonstrates Reduced Mortality Rates in Patients with Pulmonary Embolism

Retrieved on: 
Thursday, March 7, 2024
Software, General Health, Professional Services, Data Management, Medical Devices, Technology, Infectious Diseases, Hospitals, Artificial Intelligence, Health Technology, Data Analytics, Health, Viz, Pulmonary embolism, Multimedia, AI, AVF, Assessment, TriHealth, Mortality, American Venous Forum, PERT, Medical device

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced clinical data validating the impact of the Viz PE Solution in the management and outcomes of patients with pulmonary embolism (PE).

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced clinical data validating the impact of the Viz PE Solution in the management and outcomes of patients with pulmonary embolism (PE).
  • The data was presented during the 2024 AVF (American Venous Forum) by Jacob Shapiro, M.D., vascular surgeon at TriHealth in Cincinnati, OH.
  • View the full release here: https://www.businesswire.com/news/home/20240307999862/en/
    The real-world study, "Shorter Time to Assessment and Anticoagulation with Decreased Mortality in Patients with Pulmonary Embolism Following Implementation of Artificial Intelligence Software," evaluated the clinical impact of the Viz PE Solution on time to assessment, time to anticoagulation, and patient outcomes at TriHealth.
  • The study found that implementation of the AI-powered solution combined with PERT activation significantly improved time to assessment and time to anticoagulation with a 74% reduction in in-hospital mortality risk.

Viz.ai Receives FDA 510(k) Clearance for Artificial Intelligence Algorithm for the Quantification of Intracerebral Hemorrhage

Retrieved on: 
Thursday, February 8, 2024
Technology, Hospitals, FDA, Health Technology, Cardiology, Software, Practice Management, Health, Data Management, Artificial Intelligence, Radiology, Viz, Neurology, Brain, FRCSC, NCCT, Food, Food and Drug Administration, ICH, AI, University, UTHealth School of Dentistry, MPH, Multimedia, Neurosurgery, Hospital, Stroke, Lateral ventricles, Disease, Intracerebral hemorrhage

“This technology, which marries precision with AI, is poised to transform how we approach intracerebral hemorrhage cases."

Key Points: 
  • “This technology, which marries precision with AI, is poised to transform how we approach intracerebral hemorrhage cases."
  • Intracerebral hemorrhage accounts for up to 15% of all strokes and has high morbidity and mortality rates, demanding swift response.
  • Accurate volume measurements of brain bleeds are crucial for assessing the severity of cases, monitoring progression, and planning treatment strategies.
  • Viz ICH Plus exemplifies our dedication to enhancing patient care by leveraging technology," stated Jayme Strauss, chief clinical officer at Viz.ai.

Viz.ai Announces Six Clinical Studies that Further Validate Impact of Viz™ Neuro Suite on Patient Care

Retrieved on: 
Wednesday, February 7, 2024
Software, Research, General Health, Technology, Medical Devices, Infectious Diseases, Hospitals, Artificial Intelligence, Health Technology, Clinical Trials, Science, Neurology, Health, Shift, CNN, Conference, ISC, Atrial fibrillation, DTG, Neurosurgery, Workflow, FAHA, Diagnosis, ICM, Aneurysm, Intraparenchymal hemorrhage, AI, MLS, Automation, MD, Single Center, Abstract (summary), Stroke, Viz, ICH, Patient, Groin, Triage, Intervention, Artificial intelligence, CSC, UIA, Intracranial hemorrhage, Associate, University of Kentucky, University, McGovern Medical School, Ambient occlusion, Medical device

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in neurovascular care.

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in neurovascular care.
  • “As a leader in AI-powered stroke detection and care coordination, Viz.ai does not rest on what we have done, but instead continues to invest in proving the accuracy and impact of our comprehensive Viz Neuro Suite,” said Molly Madziva Taitt, VP, Global Clinical Affairs.
  • This study is the first of its kind to assess the impact of AI in the acute stroke workflow based on user engagement.
  • For more information on the Viz Neuro Suite, visit https://www.viz.ai/neuro .

Viz.ai Adoption Surpasses 1,500 Hospitals Nationwide

Retrieved on: 
Monday, January 8, 2024
Technology, Hospitals, Health Technology, Cardiology, Software, Practice Management, Health, Data Management, Artificial Intelligence, Viz, Partnership, Pulmonary embolism, FDA, CTPA, Workflow, Hospital, MD, AI, HCM, Publication, Patient, Diagnosis, Hypertrophic cardiomyopathy, Cardiovascular disease, Health information management, Electronic health record, Algorithm, Medical device

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced that the company has surpassed adoption in 1,500 hospitals in the United States, including the majority of the 50 largest healthcare systems.

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced that the company has surpassed adoption in 1,500 hospitals in the United States, including the majority of the 50 largest healthcare systems.
  • The company also forged 4 new strategic partnerships with life science customers, now capping 7 of the top 30 life science companies in the world.
  • With life science support, Viz.ai develops and deploys AI-powered solutions across its vast footprint to streamline patient journeys and accelerate speed to diagnosis and therapy.
  • “This was a momentous year marked by continued adoption of our AI-powered care coordination solution.

New Clinical Data Supports Viz.ai Solution for Improved Pulmonary Embolism Detection and Care Coordination

Retrieved on: 
Thursday, September 21, 2023
Nursing, Cardiology, Technology, Health, Health Technology, Medical Devices, Apps, Applications, Software, Artificial Intelligence, Hospitals, Surgery, PE, Use, Workflow, Temple University, Pulmonary embolism, VPS Healthcare, Research, TriHealth, PERT, Viz, Triage, Patient, Treatment, Algorithm, Artificial intelligence, AI, Detection, CTPA, Dentistry, Medical device, Medicine

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in pulmonary embolism (PE) detection.

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in pulmonary embolism (PE) detection.
  • Two studies have demonstrated the real-world clinical efficacy of Viz.ai's PE Module to quickly and accurately identify PE and associated right heart strain, accelerate care coordination, and improve healthcare workflow efficiency.
  • Pulmonary embolism is a severe medical condition, which affects around 900,000 people in the U.S. every year, and often challenging to diagnose and treat due to overlapping symptoms with other diseases.
  • The study found that, across 100 retrospectively-collected chest CTPA images, Viz PE demonstrated a sensitivity of 91.1% and specificity of 100.0%.